BIIB - BIIB STOCKHOLDERS: Lead Plaintiff Deadline Approaching in Biogen Inc. Class Action; Contact Robbins LLP | Benzinga
SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Biogen Inc. (NASDAQ:BIIB) securities between February 3, 2022 and February 13, 2024. Biogen is a global biopharmaceutical company that discovers, develops, and delivers therapies for people living with serious and complex diseases worldwide.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that Biogen Inc. (BIIB) Misled Investors Regarding its Financial Prospects
According to the complaint, during the class period defendants failed to disclose that: (i) Biogen had overstated its efforts to enhance its transparency, corporate governance, and compliance controls and procedures, as well as the efficacy of those controls and procedures; (ii) accordingly, Biogen maintained inadequate compliance controls and procedures in connection with its business operations in foreign countries; (iii) Biogen and/or its employees were engaged in unlawful or otherwise improper conduct in several foreign countries; (iv) the foregoing subjected the Company to a heightened risk of governmental and/or ...